Drug Pricing - Pharmacist Digest

STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices

STAT

MARCH 10, 2023

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. Continue to STAT+ to read the full story…

Drug Pricing

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Pharmaceutical Technology

APRIL 25, 2024

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

Drug Pricing

Drug Pricing Diabetes

Amylyx ALS drug draws criticism over $158,000 price tag

pharmaphorum

OCTOBER 3, 2022

The third ALS treatment to be given FDA approval, following Mitsubishi Tanabe’s Radicava ($170,000 per year) and generic drug riluzole – Relyvrio is priced at around $12,500 per 28-day prescription. Following news of Relyvrio’s $158,000 annual price tag, both ALS advocates and outside observers have voiced outrage at the cost.

Drug Pricing

STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps

STAT

APRIL 12, 2024

The original bill was introduced over concerns that patients may lose access to rare disease drugs if companies halt sales or decide not to invest in developing such medicines. Continue to STAT+ to read the full story…

Drug Pricing

STAT+: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions

STAT

JANUARY 6, 2023

Food and Drug Administration has granted accelerated approval to the widely anticipated Alzheimer’s drug from Eisai and Biogen, a key question is the extent to which payers — private and public — will cover the treatment. Such decisions are based on myriad factors, starting with the average $26,500 price tag.

Drug Pricing

STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap

STAT

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

Drug Pricing

Drug Pricing Diabetes

STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty

STAT

OCTOBER 6, 2022

… Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” according to Stuart Arbuckle, chief operating officer at Vertex Pharmaceuticals, which is preparing to market its own treatment for sickle-cell disease , Bloomberg News tells us. Even

Drug Pricing

STAT+: Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages

STAT

OCTOBER 27, 2022

Over the past week, Areva Pharmaceuticals began marketing vials of fludarabine at a wholesale price of $2,736, a much steeper cost than the $272 charged for the same dosage by Fresenius Kabi and the $109 price tag from Teva Pharmaceuticals, according to data from IBM Micromedex, which gathers pricing data that is reported by manufacturers.

Dosage

Dosage Drug Pricing

STAT+: Lawmakers tell Pfizer CEO to ‘back off’ on planned price hike for Covid-19 vaccine

STAT

DECEMBER 13, 2022

argued the planned price tag is nearly four times the current $30 price paid by the U.S. A pair of U.S. ” In their letter, U.S. Elizabeth Warren (D-Mass.) Peter Welch (D-Vt.) government and also represents a 10,000% markup over what some researchers have calculated as the cost to produce the vaccine.

Vaccines

Vaccines Drug Pricing

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

JUNE 8, 2021

GlobalData does see the approval of Aduhelm encouraging more research on combination therapies, for example with anti-tau drugs. The post FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag appeared first on.

Labelling

Labelling Drug Pricing

Comparing Namenda XR and Memantine – Cash is King

Med Ed 101

APRIL 7, 2019

Namenda XR comes in with a price tag of about $500 dollars per month. I feel like I’m still seeing quite a bit of Namenda XR being used. The generic version of Namenda (memantine) is an immediate release formulation that is probably going to cost less than $50/month. Source When comparing Namenda XR and memantine, […].

Drug Pricing

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

JUNE 29, 2022

In a series of data-driven deep dives, we will examine how the development of orphan drug therapies has evolved over the years, and use the FDA’s orphan drug program as a barometer of these advances. However, extended market exclusivity is often associated with high drug pricing and limited patient access.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development

Orphan drugs’ financial success raises questions

pharmaphorum

JUNE 2, 2022

And of course, in many cases, these drugs have higher than average price tags compared to the wider market which is due to the limited – or in most cases – non-existent competition within a treatment area.”. Raising questions.

Compounding

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing

Ep. 005 – Dave Chase Podcast Transcript

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication.

Health and Personal Care Stores

Health and Personal Care Stores Mayo Clinic Hospitals Specialty Pharmacies

Pharmacist Digest

STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Trending Sources

Amylyx ALS drug draws criticism over $158,000 price tag

STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps

STAT+: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions

STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap

STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty

STAT+: Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages

STAT+: Lawmakers tell Pfizer CEO to ‘back off’ on planned price hike for Covid-19 vaccine

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

Comparing Namenda XR and Memantine – Cash is King

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Orphan drugs’ financial success raises questions

Ep. 005 – Dave Chase Podcast Transcript

Stay Connected